Immunogenicity of an inactivated monovalent 2009 influenza A (H1N1) vaccine in patients who have cancer

Oncologist

Volumn 17, Issue 1, 2012, Pages 125-134

  Xu, Yiqing ^a   Methuku, Nanda ^a   Coimbatore, Praveena ^a   Fitzgerald, Theresa ^b   Huang, Yiwu ^a   Xiao, Ying Yi ^a   Pagala, Murali ^a   Gupta, Shachi ^c   Solomon, William ^a   Rubin, Philip ^a   Treanor, John ^b   Astrow, Alan ^a   Minkoff, Howard ^a   Cooper, Jay S ^a  

^a MAIMONIDES MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

H1N1; Immune response; Immunosuppression; Myelosuppression; Vaccination

Indexed keywords

INFLUENZA VACCINE;

2009 H1N1 INFLUENZA; ADULT; ANTIBODY TITER; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HEMATOLOGIC MALIGNANCY; HORMONAL THERAPY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROCONVERSION; SOLID TUMOR;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES;

EID: 84863012760     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0220     Document Type: Article

References (53)

1. Barker WH, Mullooly JP. A study of excess mortality during influenza epidemics in the United States, 1968-1976. Am J Epidemiol 1982;115: 479-480.
2. Elting LS, Whimbey E, LoWet al. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Support Care Cancer 1995;3:198-202.
3. Couch RB, Englund JA, Whimbey E. Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med 1997;102: 2-9.
4. Schepetiuk S, Papanaoum K, Qiao M. Spread of influenza A virus infection in hospitalised patients with cancer. Aust N Z J Med 1998;28:475-476.
5. Whimbey E, Elting LS, Couch RB et al. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant 1994;13:437-440.
6. Fiore AE, Shay DK, Broder K et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWRRecomm Rep 2008;57(RR-7):1-60.
7. Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009;58(RR-10):1-8.
8. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009;9:493-504.
9. Pollyea DA, Brown JM, Horning SJ. Utility of influenza vaccination for oncology patients. J Clin Oncol 2010;28:2481-2490.
10. Shildt RA, Luedke DW, Kasai G et al. Antibody response to influenza immunization in adult patients with malignant disease. Cancer 1979;44: 1629-1635.
11. Mazza JJ, Yale SH, Arrowood JR et al. Efficacy of the influenza vaccine in patients with malignant lymphoma. Clin Med Res 2005;3:214-220.
12. Lo W, Whimbey E, Elting L et al. Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy. Eur J Clin Microbiol Infect Dis 1993;12:778-782.
13. Brydak LB, Machala M, Centkowski P et al. Humoral response to hemagglutinin components of influenza vaccine in patients with non-Hodgkin malignant lymphoma. Vaccine 2006;24:6620-6623.
14. Stiver HG, Weinerman BH. Impaired serum antibody response to inactivated influenza A and B vaccine in cancer patients. Can Med Assoc J. 1978; 119:733-735, 738.
15. Anderson H, Petrie K, Berrisford C et al. Seroconversion after influenza vaccination in patients with lung cancer. Br J Cancer 1999;80:219-220.
16. Centkowski P, Brydak L, Machala M et al. Immunogenicity of influenza vaccination in patients with non-Hodgkin lymphoma. J Clin Immunol 2007;27:339-346.
17. Yee SS, Dutta PR, Solin LJ, Vapiwala N, Kao GD. Lack of compliance with national vaccination guidelines in oncology patients receiving radiation therapy. J Support Oncol 2010;8:28-34.
18. Loulergue P, Mir O, Alexandre J, Ropert S, Goldwasser F, Launay O. Low influenza vaccination rate among patients receiving chemotherapy for cancer. Ann Oncol 2008;19:1658.
19. Demetri GD, von MM, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
20. Ratain MJ, Eisen T, StadlerWMet al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-2512.
21. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renalcell carcinoma. N Engl J Med 2007;356:115-124.
22. Erlotinib package insert. Genentech, South San Francisco, CA, April 2010.
23. Stopeck AT, Unger JM, Rimsza LM et al. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leuk Lymphoma 2009;50:728-735.
24. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-2048.
25. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726.
26. Haskell CM. Immunologic aspects of cancer chemotherapy. Annu Rev Pharmacol Toxicol 1977; 17179-17195.
27. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995;13:2431-2448.
28. Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010;47:115-123.
29. Influenza A. (H1N1) 2009 Monovalent Vaccine package insert. Sanofi Pasteur, September 2009.
30. Rowe T, Abernathy RA, Hu-Primmer J et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999;37:937-943.
31. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of Pandemic influenza vaccines. Available at http:// www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/ Guidances/Vaccines/ucm091985.pdf. Accessed March 30, 2011.
32. Committee for Proprietary Medicinal Products. Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. London: European Medicines Agency. Available at http:// www.emea.europa.eu/pdfs/human/bwp/021496en. pdf. Accessed March 30, 2011.
33. Nolan T, McVernon J, Skeljo M et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010;303:37-46.
34. Greenberg ME, Lai MH, Hartel GF et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009;361:2405-2413.
35. Clark TW, Pareek M, HoschlerKet al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009;361:2424-2435.
36. Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004;103:133-138.
37. Schafer AI, Churchill WH, Ames P et al. The influence of chemotherapy on response of patients with hematologic malignancies to influenza vaccine. Cancer 1979;43:25-30.
38. Ganz PA, Shanley JD, Cherry JD. Responses of patients with neoplastic diseases to influenza virus vaccine. Cancer 1978;42:2244-2247.
39. Ortbals DW, Liebhaber H, Presant CA et al. Influenza immunization of adult patients with malignant diseases. Ann Intern Med 1977;87:552-557.
40. Agresti A, Coull BA. Approximate is better than "exact" for interval estimation of binomial proportions. American Statistician 1998;52119-52126.
41. Vajo Z, Tamas F, Sinka L et al. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 2010;375:49-55.
42. Rousseau B, Loulergue P, Mir O et al. Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study. Ann Oncol 2011, in press.
43. Mackay HJ, McGee J, Villa D et al. Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment. J Clin Virol 2011;50:212-216.
44. de Lavallade H, Garland P, Sekine T et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica 2011;96:307-314.
45. Balter S, Gupta LS, Lim S et al. Pandemic (H1N1) 2009 surveillance for severe illness and response, New York, New York, USA, April-July 2009. Emerg Infect Dis 2010;16:1259-1264.
46. Hancock K, Veguilla V, Lu X et al. Crossreactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009;361: 1945-1952.
47. Robertson JD, Nagesh K, Jowitt SN et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer 2000;82:1261-1265.
48. Sommer AL, Wachel BK, Smith JA. Evaluation of vaccine dosing in patients with solid tumors receiving myelosuppressive chemotherapy. J Oncol Pharm Pract 2006;12:143-154.
49. Arrowood JR, Hayney MS. Immunization recommendations for adults with cancer. Ann Pharmacother 2002;36:1219-1229.
50. Molinari NA, Ortega-Sanchez IR, Messonnier ML et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007;25:5086-5096.
51. Gross PA, Lee H, Wolff JA et al. Influenza immunization in immunosuppressed children. J Pediatr 1978;92:30-35.
52. Brown AE, Steinherz PG, Miller DR et al. Immunization against influenza in children with cancer: results of a three-dose trial. J Infect Dis 1982; 145:126.
53. Chisholm J, Howe K, Taj M et al. Influenza immunisation in children with solid tumours. Eur J Cancer 2005;41:2280-2287.